Report : North America Urinalysis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Consumables and Instruments), Test Type (Pregnancy and Fertility Tests, Biochemical Urinalysis, and Sediment Urinalysis), Application (Disease Screening and Pregnancy and Fertility), and End User (Hospitals and Clinics, Diagnostic Laboratories, Home Care Settings, Research Laboratories, and Institutes)
Consumables Segment to Dominate North America Urinalysis Market during 2020–2028
According to a new market research study on “North America Urinalysis Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product, Test Type, Application, End User” is expected to reach US$ 2,129.13 million by 2028 from 1,432.01 US$ million in 2021. The market is estimated to grow at a CAGR of 5.8% from 2021 to 2028. The report provides trends prevailing in the North America urinalysis market along with the drivers and restraints pertaining to the market growth. Rising cases of urinary tract infection, diabetes, and kidney diseases is the major factor driving the growth of the North America urinalysis market. However, issues associated with strict regulatory protocols and product fails hinders the growth of North America urinalysis market.
North America urinalysis market is segmented into product, test type, application, end user, and country. Based on product, the North America urinalysis market is segmented into consumables and instruments. The consumables segment is expected to hold a larger market share in 2021. The North America urinalysis market, based on test type, is segmented into pregnancy and fertility tests, biochemical urinalysis, and sediment urinalysis. The biochemical urinalysis segment would hold the largest share of the market in 2021. Based on application, the North America urinalysis market is segmented into disease screening and pregnancy, and fertility. The disease screening segment would account for a larger market share in 2021. The North America urinalysis market, by end user, is segmented into hospitals and clinics, diagnostic laboratories, home care settings, and research laboratories and institutes. The hospitals and clinics segment would hold the largest share of the market in 2021. Based on country, the North America urinalysis market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2021.
Lockdowns enacted by various North American countries to control the spread of COVID-19 caused people to delay undergoing health checkups, thus affecting the number of tests performed and sales of instruments, consumables, and reagents. However, a resurgence in testing numbers is seen as countries gradually ease the restrictions imposed on movement. According to National Kidney Foundation, people hospitalized with COVID-19 are at a significant risk of acute kidney injury (AKI), leading to serious illness, dialysis, and death. For the recovered COVID-19 patients who had an AKI or acute renal failure, urinalysis diagnosis is recommended since the risk of developing chronic kidney disease is higher in them than others. COVID-19 patients who did not develop an AKI, but had blood and/or protein in their urine, need to be monitored as they are at a greater risk of developing chronic- and end-stage kidney disease. COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers are facing unprecedented challenges. Regulatory authorities utilized methods to speed approval of diagnostic products. Companies have taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities. For instance, in August 2020, Sysmex America, Inc., a leading diagnostic solutions company, entered into a distribution agreement with Siemens Healthineers to increase the distribution of the CLINITEK Novus automated urine chemistry analyzer platform. Therefore, in the long run, upon the streamlining of the COVID-19 vaccination programs and the decrease in transmission rates, healthcare systems will return to normal and generate significant demand urinalysis products and services.
Abbott; ACON Laboratories, Inc.; ARKRAY, Inc.; Beckman Coulter, Inc.; Bio-Rad Laboratories Inc.; Cardinal Health Inc; F. Hoffmann-La Roche Ltd.; Quidel Corporation; Siemens Healthineers AG; and Sysmex Corporation are among the leading companies in the North America urinalysis market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Beckman Coulter launched its DxU Iris Workcell at the AACC (American Association for Clinical Chemistry) Annual Scientific Meeting & Clinical Lab Expo. The DxU Iris Workcell, a fully automated system that reduces manual sample processing in urinalysis lab workflow by manual reviews reduction to 4%. The DxU Iris Workcell pairs the DxU 850m Iris or DxU 840m Iris urine microscopy analyzer with the Arkray AUTION MAX 4030 urine chemistry analyzer to create a scalable, fully automated urinalysis solution. High-volume clinical labs can use the system.
Contact Person: Sameer Joshi
Email Id: email@example.com